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                                                      ABSTRACT  
 
Several tests are available for evaluation of respiratory disorders but most of them 
are invasive and associated with some risk or patient discomfort. Examples 
include bronchoscopy (bronchoalveolar lavage, BAL) [1], venopuncture [2] and 
sputum induction [3]. Noninvasive sampling of nongaseous substances contained 
in expired air,  collected as exhaled breath condensate (EBC) has been used to 
detect inflammatory markers and by-products including nitric oxide and 
arachidonic acid metabolites and proteins [4]. Nerve growth factor (NGF) is a 
protein that has been implicated in neurogenic airway inflammation and this pilot 
study aimed to develop a non-invasive approach for evaluation of allergic airway 
inflammatory disease by measuring and comparing levels of NGF in the induced 
sputum and EBC of ten (10) asthmatics and ten (10) non-asthmatics. 
Though twenty (20) subjects were sampled, an unexpected event due to a 
defective NGF kit inadvertently resulted in an unsuccessful analysis of fifteen  
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(15) sets of specimen (6 non-asthmatics and 9 asthmatics), limiting the study. 
This study is significant because occupational lung diseases are the number one 
work-related illness in the United States and occupational asthma is the most 
common form [9]. Toluene diisocyanate (TDI) is the commonest cause of 
occupational asthma and workers exposed to TDI vapor may develop 
inflammatory conditions including asthma, rhinitis and nasal irritation [7]. 
Results: NGF was detected and measured only in sputum, with a mean NGF level 
of 210 (210-210, range 0) in asthmatics and 164 (7-280, range 273) in non-
asthmatics. Nonetheless, we failed to reject the null hypothesis (number 3). 
Conclusion: This limited study did not have adequate power (power 11%) due to 
the small sample size and thus lacks internal validity. Further studies are needed 
using a larger sample size.   
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                                                        INTRODUCTION 
Diseases and the work environment 
Bernardino Ramazzini, the "father of occupational medicine," was the first to 
write about the effects of workplace hazards in causing some diseases over three hundred 
years ago [8]. In the 21st century, toxic exposures and other unique hazards found in the 
workplace continue to have a significant impact on public health.  
A disease or disability resulting from the conditions of a person’s employment, 
work, trade or occupation is called an occupational disease, illness or work related injury. 
It usually but not always occurs following long exposure to a noxious substance or from 
continuous repetition of certain acts. Occupational lung diseases are the commonest cause 
of work-related illness in the United States [9]. In 2002, there were about 294,500 newly 
reported cases of occupational illness in the private industry, and 22,000 newly reported 
respiratory conditions [9]. Overall, 2.5 per 10,000 full time workers developed nonfatal 
occupational respiratory diseases [9]. The total cost of occupational injuries and illnesses 
in the United States exceeds $170 billion per year [9]. 
 
Occupational lung diseases 
Occupational lung diseases are the number one work-related illness in the United 
States based on the frequency, severity, and preventability of diseases [9]. Though these 
illnesses are usually caused by prolonged exposure to irritating or toxic substances  
      1 
  
which may result in acute or chronic respiratory ailments, severe single exposures can 
also lead to chronic lung disease.  Smoking may act synergistically to increase the 
severity of these diseases.  
Occupational lung diseases are often not curable, but are always preventable [9]. 
Improving ventilation, wearing protective equipment, changing work procedures, and 
educating workers are the key factors for prevention [9]. Examples of the commoner 
occupational lung diseases include occupational asthma (commonest), occupational lung 
cancer, asbestosis, mesothelioma, byssinosis, coal workers’ pneumoconiosis, silicocis 
and hypersensitivity pneumonitis [9]. 
 
Occupational asthma   
Occupational asthma is defined as asthma caused by work exposure [10]. It is 
characterized by recurrent episodes of respiratory symptoms, variable airflow 
obstruction, airway hyperreactivity and chronic airway inflammation [10]. 
Chronic inflammation may lead to airway remodeling. The term "airway 
remodeling" refers to structural changes that occur in conjunction with, or because of, 
chronic airway inflammation and its consequences include incompletely reversible airway 
narrowing, bronchial hyper-responsiveness, airway edema, and mucus hypersecretion, 
which may predispose subjects with asthma to exacerbations and even death due to 
airway obstruction.     
Surveillance programs established around the world have determined that 
diisocyanate chemicals are the most common cause of occupational asthma. In the United 
States approximately 100,000 workers are exposed to these chemical compounds in the                  
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workplace each year and 5-10% of these workers will develop occupational asthma. In 
industrialized countries, occupational factors have been implicated in 9 to 15 % of all 
cases of adult asthma [11, 12].  
There are two types: (i) immunologic type, characterized by a latency period 
before onset of symptoms and (ii) nonimmunologic type, which occurs after single or 
multiple exposures to high concentrations of a workplace irritant material in the absence 
of a latency period [13]. Work-aggravated asthma is also well defined, and is preexisting 
or concurrent asthma exacerbated by workplace exposures [13]. Variant syndromes have  
been described too [13]. Clinical history obtained with use of questionnaires has a high 
sensitivity (87-92%) and low specificity (14-32%) for diagnosis, but is less reliable for 
recognition of airway hyperresponsiveness. A methacholine challenge test is preferred for 
this. In addition to assessment of airway hyperresponsiveness, noninvasive assessment of 
airway inflammation can be used to diagnose occupational asthma. 
The best treatment for occupational asthma is primary prevention by hazard 
abatement in the form of removal of the offending agent and substitution of a nontoxic 
agent. Strict exposure control is needed when asthma is induced by a workplace sensitizer 
and this can be achieved preferably by engineering control to protect all employees in the 
work area or respirator (personal protective equipment) use to protect specific 
individuals. Rhinitis is associated with an increased risk of asthma regardless of atopic 
status and occupational rhinoconjunctivitis can lead to occupational asthma [14].   
Screening and monitoring for rhinitis and or rhinoconjunctivitis during pre-
employment physical examinations and as part of a health surveillance program may help      
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in early detection of sensitized workers and promote early intervention necessary to 
prevent progression to occupational asthma. This would be expected to result in a 
significant reduction in the incidence of occupational asthma.  
 
Methods used to study respiratory diseases  
Inflammation is a component of several diseases of the upper and lower 
respiratory tract including rhinitis, asthma, chronic obstructive pulmonary disease and 
bronchiectasis. Typically it is assessed directly by performing invasive procedures such 
as bronchoalvelar lavage and bronchial biopsy or indirectly by venopuncture, though the 
use of these procedures in clinical practice is limited. Another common and well 
validated method is sputum induction which is non-invasive but often causes great 
discomfort to patients [10]. As a result of this, researchers continued to search for 
alternative methods of assessing airway inflammation that is neither invasive nor 
uncomfortable.  
Recently, two new noninvasive methods were introduced. First, is the 
measurement of exhaled nitric oxide which reveals increased levels in the exhaled air 
from asthmatic patients that can be decreased by corticosteroid therapy, however, a few 
occupational studies that have been done to assess the its role in occupational asthma 
revealed inconsistent results [10]. The usefulness of exhaled nitric oxide is the 
investigation of occupational asthma is limited by confounding factors such as therapy 
with inhaled steroids and smoking, thus it has a high sensitivity but low specificity [10].  
The second noninvasive method is the detection of markers (e.g. isoprostanes and      
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aldehydes) and mediators (prostaglandins and leukotrienes) in exhaled breath condensate 
[10]. Noninvasive sampling of nongaseous substances contained in expired air, which can 
be collected as exhaled breath condensate (EBC) has been used to detect markers of 
inflammatory processes including arachidonic acid metabolites and proteins. 
Because serial measurements can be made with no harmful effects, it is possible that this 
method could be useful in occupational medicine [10].     
Both methods described above use exhaled air, which is usually warm and 
humidified. Exhaled air contains gases, water vapor, and various volatile substances that 
come from the airways and the fluid that lines the airways.   Several of these dissolved 
substances have been shown to be markers of airway disease and or inflammation.  
Because exhaled air is easily obtained in a non-invasive manner with minimal discomfort 
to patients, it has great potentials for routine use in clinical practice for screening and 
diagnosing airway inflammation, as well as monitoring patient’s response to treatment. 
However, measurements of markers in exhaled breath can vary based on the parameters 
used to study them.  Results may vary based on type of equipment used, the exhalation 
duration, the method of acquiring samples, and the expiratory flow rate. 
 
Nerve growth factor (NGF) 
NGF is a neurotrophin produced locally in the human airways. Increasing 
evidence suggests that NGF may also be an important inflammatory mediator [1]. The 
first report that serum level of NGF was increased in human allergic inflammatory 
diseases including asthma, rhinoconjunctivitis and urticaria-angioedema was in 1996.  
      5  
  
Patients with more than one allergic disease had higher NGF serum values than those 
with a single disease [2]. Healthy subjects also produce NGF in their airways but at lower 
levels compared to persons with allergic airway disease.  
In vitro studies have shown that NGF is synthesized and secreted by structural 
cells (human lung fibroblasts, airway epithelial cells and smooth muscle cells) and cells 
of the immune system (lymphocytes, monocytes, macrophages, eosinophils and mast 
cells). NGF exerts a central role in the development, differentiation and function of 
neuronal and immune cells [6]. NGF induces sensory and sympathetic hyper-innervation 
of the airways, which leads to increased airway reactivity upon provocation with 
capsaicin or using electrical field stimulation, and increased systematic and airway levels 
of tachykinins can be induced by an allergen challenge in asthmatics.  
Animal studies indicate that NGF alters sensory nerve function and promotes 
allergic inflammation (via neurokinin 1, NK-1), bronchial hyper-reactivity and airway 
obstruction (via neurokinin 2, NK-2) and regulation of tachykinin synthesis has been 
implicated as the mediator [6]. The fact that these effects of NGF can be blocked by a 
tachykinin receptor antagonist, coupled with the elevated levels of substance P (a 
tachykinin) found in the lungs of asthmatics during an acute attack further support this. 
Substance P has a high affinity for NK-1 receptors. Transient increases in substance P 
protein have been demonstrated in sensory cell bodies innervating respiratory epithelium 
of the nose or lung following antigen challenge , toluene diisocyanate (TDI) exposure, 
viral infection and asphalt fume exposure [7].  Previous studies have shown that exposure 
to TDI results in elevated NGF levels and this precedes the inflammatory changes [7].   
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NGF measurement in blood, bronchoalveolar lavage (BAL) fluid, nasal lavage 
fluid, and sputum is well documented in the medical literature using invasive techniques 
such as endoscopy, venopuncture and sputum induction [1,2,3,5]. However, a literature 
review revealed no evidence of studies on NGF measurement in exhaled breath 
condensate.  
 
Research questions 
1.) Can nerve growth factor (NGF) be measured in induced sputum and exhaled 
breath condensate (EBC)? 
2.) If so, how do levels differ between asthmatics and non-asthmatic subjects? 
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                                                        HYPOTHESIS 
To study this, NGF is measured in exhaled breath condensate and induced sputum 
while comparing asthmatics with non-asthmatics. The first Null hypothesis states that 
NGF is not measurable in induced sputum. The first alternate hypothesis states that NGF 
can be measured in induced sputum. The second Null hypothesis states that NGF is not 
measurable in EBC. The second alternate hypothesis states that NGF can be measured in 
EBC. The third Null hypothesis states that there is no difference in the levels of NGF 
measured in the sputum of asthmatic persons compared to non-asthmatic persons. The 
third alternate hypothesis states that higher levels of NGF can be measured in the sputum 
of asthmatic persons compared to non-asthmatic persons. The fourth Null hypothesis 
states that there is no difference in the levels of NGF measured in the EBC of asthmatic 
persons compared to non-asthmatic persons. The fourth alternate hypothesis states that 
higher levels of NGF can be measured in the EBC of asthmatic persons compared to non-
asthmatic persons. 
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                                            GOALS AND OBJECTIVES 
This study aims to develop a non-invasive approach to evaluation of airway 
inflammation and disease, especially in persons with allergic conditions using exhaled 
breath condensate. 
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                       SIGNIFICANCE AND UTILITY OF RESEARCH  
This study is unique because non-invasive techniques are currently not available for 
routine measurement of NGF. If NGF is detected and consistently measured in EBC, this 
may represent a safe, easy and non-invasive alternative approach for evaluation of 
allergic airway inflammation and diseases. Furthermore, since rhinitis is associated with 
an increased risk of asthma regardless of atopic status, screening and monitoring for  
rhinoconjunctivitis as part of a preemployment physical and health surveillance program 
may help in the early detection of possibly sensitized workers and promote early 
intervention necessary to prevent progression to occupational asthma. The end result will 
be a significant reduction in the incidence of occupational asthma. Furthermore, 
measurement of NGF levels may be useful in the assessment of exposure in irritant 
induced asthma (Reactive Airways Dysfunction Syndrome) and lastly, new drugs that 
target NGF may be developed in the future for treatment of asthma.  
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                                   MATERIALS AND METHODS 
Overall study design 
In this pilot study, the variable studied was asthmatic versus non-asthmatic status 
and the outcome of interest was levels of the marker nerve growth factor (NGF) in 
induced sputum and exhaled breath condensate.  A cross sectional study design was 
utilized where individual specimens were collected, processed, stored and analyzed to 
obtain relevant data.   
Twenty people were divided in two groups of ten.  The first group was made up 
of asthmatics with mild disease while the second group constituted non-asthmatics.  The 
study population was otherwise made up of healthy, non-pregnant persons aged 18-50 
years old.  Health was defined as having a negative history of heart disease, fever or 
respiratory tract infection within 96 hours prior to participating, chronic lung disease and 
moderate asthma or worse.  Persons on daily maintenance therapy for asthma including 
beta-2 agonist bronchodilators and steroids were excluded.   
 
Facilities and equipment 
The participants were seen at the College of Public Health at the University of 
South Florida in the Breath Laboratory (MHH Room 323).  The records were maintained 
in a secured cabinet in this room.  The key to access the laboratory was distributed by the  
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University of South Florida only to authorized personnel (obtained through the College of  
Public Health).  The necessary equipment discussed above that was needed to perform 
this project was available in this room. 
 
Participant recruitment 
Healthy subjects were asked to volunteer for the study performed during a single 
visit lasting approximately ninety minutes at the Breath Laboratory located in the College 
of Public Health (MHH Room 323).   Subjects who expressed a willingness to volunteer 
were invited to the Breath laboratory and given information about the study aim, 
procedure, risks and benefits, and the alternatives to the procedure.  They were 
questioned to demonstrate an understanding of all that was discussed.  Throughout the 
encounter subjects were encouraged to ask questions at any time.  Afterwards, willing 
subjects were then required to sign an informed consent before proceeding with the study. 
They were monitored by a physician throughout the encounter by direct observation.   
Prior to participating in the study and undergoing spirometry, subjects were advised not 
to eat or drink anything and to refrain from strenuous exercise as recommended in the 
American Thoracic Society (ATS) guidelines [15]. 
 
Study subjects and restrictions  
Only normal healthy, non-pregnant people aged 18-50 years old and those with a 
self reported history of mild asthma were invited to participate in the study with the 
following exceptions. A history of heart disease, fever or respiratory tract infection within    
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96 hours prior to participating, chronic lung disease, moderate asthma or worse and daily 
maintenance therapy for asthma with bronchodilators and steroids are all exclusion 
criteria. Subjects were also required to refrain from strenuous exercise, food and drinks at 
least one hour prior to the test as recommended by the American Thoracic Society [19]. 
 
Study questionnaire and eligibility 
Each subject was required to fill out a pre-study questionnaire on the day of the 
study after consenting to participate but prior to commencement of the study. Information 
included on this form includes age, current symptoms, past medical history, allergies, 
medications, smoking history and environmental exposure to second hand smoke.  
During each visit, subjects were also given a brief exit questionnaire to assess for change 
in symptoms and possible adverse effects from the study.  (See Appendices A and B) 
The medical history was elicited to determine health and eligibility criteria.   
Subjects who fulfilled the eligibility criteria proceeded to undergo a brief physical 
examination including auscultation of the lungs and heart.  Those subjects who remained 
eligible after questionnaire, interview, and physical examination were allowed to proceed 
to get a baseline spirometry.  To be eligible to participate in the remainder of the study,  
all participants were required to have a forced expiratory volume in one second (FEV1) 
equal or greater than 1.5L on spirometry.  
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Subject safety considerations                                                                                       
Subject safety was given the utmost consideration in this study.  Subjects were 
advised that they could choose to stop or withdraw at any time without any consequence. 
All subjects were healthy volunteers.  The entire study was non-invasive. Physical 
examination and initial medical screening questionnaires were reviewed directly by a 
physician prior to commencement of study protocol.  Only subjects who had normal 
physical examination were allowed to continue in the study.  Spirometry, which is 
commonly used in clinical practice to assess lung function, was obtained as an eligibility 
criterion.  To obtain spirometry, subjects blew out through a disposable filter (to prevent 
infection) using maximum effort after a maximal inhalation.   
Measurement of exhaled breath condensate, which is currently still a research 
tool, involved tidal breathing into the mouth piece of a cooling tube with a nose clip in 
place. This results in the trapping of moisture in the breath by condensation. This process 
was associated with less discomfort than spirometry and sputum induction.   
During each visit, subjects were also given a brief exit questionnaire to assess for any 
new symptoms or possible adverse effects from the study protocol.   
Participation in this study did not affect the standard care subjects would 
otherwise receive from their personal physicians unless abnormal finding were detected 
on physical examination and or spirometry. Under those circumstances, the subject was 
advised to consult with their personal physician. In the unlikely event that a subject 
develops an adverse effect the study will be stopped immediately despite the fact that 
most events would only be transient and subside within a few seconds to minutes of  
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stopping the activity.   In the event of persistent symptoms including chest pain or 
tightness, wheezing and dyspnea emergency equipment was available at all times during 
the study to assist the subject until the arrival of appropriate emergency personnel.  To 
ensure patient safety, all subjects were directly observed by a physician who was ACLS-
certified during the entire study protocol.  The sampling procedure was completely non-
invasive.   
 
Physical examination 
A brief physical examination with emphasis on auscultation of the lungs and heart 
was performed on all subjects prior to obtaining spirometry and proceeding with the rest 
of the study protocol. Auscultation involves listening to the breath and heart sounds with  
a stethoscope.  Person with abnormal finding were deemed ineligible  and immediately 
excluded. Such persons were advised to seek necessary medical care from their personal 
physician. Auscultation of the heart was performed for the sole purpose of subject safety.   
 
Acquisition of spirometry 
Spirometry a common clinical method used to assess lung function, was 
performed as part of the inclusion criteria for the study.  The Koko spirometer was used 
and calibrated using a standard 3-liter syringe to ambient temperature, humidity, and 
barometric pressure at least once a day on days when participants were examined.  The 
spirometer was additionally re-calibrated when at least six hours had elapsed since the 
prior calibration or at the discretion of the examiner. The raw FEV1 and FVC  
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measurements obtained for each participant were automatically compared to their 
predicted normal values based on age, ethnicity, weight, height and smoking status in 
determining their percent of predicted values using parameters as set forth by Crapo et al.  
The spirometry parameters examined on each study participant included FEV1, 
FVC, FEV1/FVC ratio, and the flow-volume loop.  At least three spirometric 
measurements were obtained on each subject, with at least one flow-volume loop 
showing good effort.  Proper technique was ensured by evaluating the flow-volume curve 
and continuance of the expiratory maneuver for at least six seconds according to ATS 
criteria. A nose-clip was placed on the subject’s nose to occlude the nostrils during 
spirometry so as to prevent nasal breathing and ensure accuracy.   Subjects were asked to 
forcibly exhale for at least six seconds through a disposable single-use filter after 
maximal inspiration, followed by another maximal inhalation. The maneuver was 
demonstrated to them to help achieve consistency.   
Subject with abnormal spirometry measurements was notified of this information 
and advised to consult their personal healthcare provider. They were subsequently 
excluded from the study.  All subjects with an FEV1/FVC ratio greater than 70% of 
predicted, FEV1 greater than 1.5 L and a normal appearing flow-volume loop were 
eligible for the study by spirometric criteria.  In those participants who did not meet all of 
these strict criteria, the overall clinical picture, including medical history and physical 
examination were assessed individually to determine study eligibility.  When eligibility 
due to spirometry did not meet these strict criteria, Dr. Stuart Brooks (faculty advisor) 
was consulted to determine whether the participant would be eligible for the study.  
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Adverse effects were unlikey to occur during this phase of the study because 
subjects identified themselves as being in good health and the test was performed with 
the patients comfortably seated in a room was temperature controlled.  Nonetheless, there 
was the slight possibility of unusual symptoms such as lightheadedness, dizziness, chest 
pains, palpitations, or shortness of breath during the spirometry from overexertion in 
breathing.  As a precaution, subjects were instructed to stop, be seated, and notify the 
physician examiner immediately if they experienced any symptoms at any time. 
 
Specimen collection  
    The study was conducted in two parts. First, exhaled breath condensate (EBC)      
   was obtained and afterwards, sputum was collected via induction. 
Exhaled breath condensate: The exhaled breath condensate was collected by using 
a condenser, which permits noninvasive collection of the nongaseous components of the 
expiratory air (EcoScreen; Jaeger, Wurzburg, Germany). The subjects were instructed to 
breathe through a device with a mouthpiece and a two-way non-rebreathing valve, which 
also serves as a saliva trap. Subjects wore a nose clip and were breathing at a normal 
frequency and tidal volume for 10 minutes. If the subjects salivated they were instructed 
to swallow. The condensate was collected in a collection cup at the base of the device and 
transferred into a microtube for immediate storage at –70°C using a micropipette. As the 
sample was taken non-invasively during tidal breathing, this method of sampling does not 
influence the sample taken as observed with other methods such as bronchoalveolar 
lavage or induced sputum.  
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Induced sputum: Prior to sputum induction, subjects were given clear and detailed 
instructions because full cooperation was needed to obtain adequate samples. Full 
resuscitation equipment was made available as recommended for specific and non-
specific bronchial challenge procedures. An ultrasonic nebulizer (DeVilbiss Pro-
UltraNeb Large olume Nebulizer099HD) with an output of 1ml per minute (1 ml/min) 
was used. Because of the risk of bronchoconstriction with use of hypertonic saline in 
asthmatic subjects, pretreatment with a bronchodilator was done on all subjects using a 
single dose of albuterol 2.5mg given over 3 minutes. Spirometry was repeated to ensure 
no significant change in FEV1 before proceeding with administration of 3% saline over 7 
minutes. 3% saline solution was administered via aerosol inhalation using a nebulizer and 
afterwards yet another spirometry was done to monitor for FEV1 changes. The process 
was stopped immediately if there was a fall in FEV1 of 20% or greater compared with the 
post-bronchodilator value or if subjects developed symptoms including lightheadedness, 
dizziness, chest pain or tightness, palpitations, dyspnea or wheezing.  
Finally, subjects were seated at a negative pressure cubicle where sputum 
expectoration was performed over a 5 – 10 minute period. The sputum was collected in a 
petri dish and processed as stated in the literature [16] prior to storage at –70°C. 
Collected sputum was checked for adequacy prior to processing by preparing a slide. 
Slide preparation entailed making a sputum smear with a loop and heat fixing it. Slide 
was stained with 1-2 drops of 1% methylene blue and allowed to stand for 1 minute 
before washing off with water. Afterwards, the slide was air dried and examined under a 
light microscope at 40x and 100x  magnifications. An adequate specimen was defined as  
18 
  
one with visible inflammatory cells (neutrophils, basophils, monocytes, eosinophils etc)  
and less than 50% squamous cells. Adequate sputum samples were immediately 
processed. First, the sample was weighed, inspected grossly and findings were recorded.  
The sputum portion of the sample (selected portion) was separated from saliva as 
much as possible using forceps and transferred to a polystyrene tube and the weigh was 
recorded. 10% dithiotreitol (DTT, Sigma chemical, St. Louis, MO, U.S.A.) equivalent to 4x 
the weight of the selected portion was added and agitated in a vortex mixer for 15 seconds. 
Afterwards the mixture was placed on a bench rocker for 15 minutes and DPBS equivalent 
to the volume of DTT used was added. The mixture was placed on a bench rocker or an 
additional 5 minutes. The mixture is then filtered through a 70 micrometer nylon 
gauze/mesh and the weight of the filtrate was recorded. Finally, the filtrate was centrifuged 
at 500 rpm for 5 minutes and the supernatant was aspirated with a micropipette and 
transferred to eppendorf micro-tubes for storage at –70°C. The stored samples are later 
analyzed for measurement of NGF using enzyme-linked immunosorbent assay (Promega, 
Madison, WI, USA, ELISA). 
 
Measurement of NGF 
ELISA: The levels of NGF protein was quantified in 1:2 diluted sputum and EBC 
samples, using a commercially available, highly sensitive NGF-specific two-site enzyme 
linked immunosorbent assay (ELISA) – kit according to the procedure indicated by the 
manufacturer (Promega, Madison, WI, USA). 96-well ELISA plates were coated with an 
anti-NGF polyclonal antibody in a coating buffer (25mm carbonate buffer, pH 9.7).                
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Following an overnight incubation at 4 degrees centigrade, the plates were washed (20mm 
Tris-HCl, 150mM NaCl with 0.05% (v/v) Tween® 20), and incubated in a blocking  
buffer for 1hour. The diluted sputum and EBC samples and the standard recombinant 
human NGF was then incubated in wells at room temperature for 6 hours, and washed 
afterwards. The 2 samples and the recombinant NGF was diluted in the blocking buffer, as 
recommended by the manufacturer. Rat monoclonal anti-NGF antibody (0.25mcg/ml) was 
added for an overnight incubation at 4 degrees centigrade, and washed afterwards. After 
washing, anti-rat horse radish peroxidase-conjugated immunoglobulin G (Ig G) was added 
and incubated for 2.5 hours at room temperature. 
Finally, the substrate (0.02% 3,3’, 5,5-tetramethylbenzidine and 0.01% hydrogen 
peroxidase) was added and incubated for 10 minutes before stopping the colorimetric 
reaction with 1N hydrochloric acid which changed the solution from blue to yellow. The 
sample absorbance or optical density was measured at 450NM within 30 minutes of 
stopping the reaction. 
 
Data collection and analysis  
Though a large study population would be required to appropriately assess the 
research questions, the analysis of exhaled breath condensate (EBC) is an evolving research 
concept and measurement of nerve growth factor (NGF) in EBC has not been reported in 
the literature. This study was embarked upon as a pilot study with the intent to follow up 
with a larger sample size in the event that NGF is detectable in significant amounts in EBC 
and sputum.  
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Twenty eligible subjects were studied to provide insight to the following  
research questions:  
(1) Can nerve growth factor (NGF) be measured in induced sputum and exhaled 
breath condensate (EBC)?  
(2.) If so, how do levels differ between asthmatics and non-asthmatic subjects? 
A power calculation was performed which was derived using alpha of 0.05 and 
power of 80%. An estimated sample size of 64 is required to show a significant difference 
in the mean of the two groups given the above parameters. In any study where there are two 
groups being compared, the participants are ideally randomly assigned to each group.  
However, random assignment is not possible when two distinct groups are being used such 
as males versus females.  A similar situation obtains in this study, where the two distinct 
groups were asthmatics versus non-asthmatics.   
The mean of each of the two groups in a study sample may be compared using a 
Student’s t-Test, a parametric analysis, when the population studied is normally distributed.  
When the population is not normally distributed, a non-parametric analysis must be used.  
Non-parametric tests include the Wilcoxon Ranked-Sum Test or the Mann-Whitney U Test.   
Statistical calculations were performed by inputting the data into Statistical 
Analysis Software (SAS), which calculated the data automatically.  For this study, SAS 
was utilized to calculate descriptive statistics such as the mean, median, variance, standard 
error of the mean, standard deviation, range, minimum and maximum values, skewness, 
and kurtosis for the non-asthmatic group.     
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                                                      STUDY RESULTS 
Exclusions 
Two asthmatic subjects who expressed their willingness to participate in the study 
were excluded because they were on daily maintenance therapy for asthma. Another non-
asthmatic study volunteer was turned down because of ongoing acute bronchitis which 
was being treated with antibiotics.  
No one was excluded on account of abnormal auscultation during physical exam.  
All the subjects had a normal cardiac exam with normal first and second heart sounds 
with regular rate and rhythm and no murmurs, gallops or rubs.  The lung exams revealed 
normal vesicular breath sounds bilaterally with no crackles, wheeze or rhonchi.  There 
was no deformity on chest exam. All subjects had FEV1 greater than 2.5 L.   
 
Study demographics 
The following tables demonstrate the results of the demographic information that 
was collected during the study.  
 Table 1.  Study population 
Groups Numbers Percentage 
Asthmatics 1 20 
Non-asthmatics 4 80 
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Table 2.  Age distribution  
  
Age 19 25 29 32 39 
Asthmatics 0 0 1 0 0 
Nonasthmatics 1 1 0 1 1 
 
Table 3.  Sex distribution 
 Male Female  
Asthmatics 0 1 1 
Non-asthmatics 3 1 4 
Total 3 2 5 
 
 
Medical Information 
The following tables list the history of allergies and smoking, co-morbidities, 
medications, allergens, physical exam findings and study adverse effects.  
Table 4.  History of Allergy 
 Asthmatics Non-asthmatics 
Positive history of allergy 1 0 
Negative history of allergy 0 4 
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Table 5. Smoking History 
  
 Asthmatics Non-asthmatics 
Never/non-smoker 1 3 
Current smoker 0 0 
Ex-smoker 0 1 
 
Table 6.  Co-morbidities 
Medical conditions Asthmatics Non-asthmatics 
Grave’s disease 1 0 
GERD 1 0 
Hypertension 0 1 
Deep Venous Thrombosis 0 1 
 
Table 7.  Medications 
Medications Asthmatics Non-asthmatics 
Synthroid 1 0 
Albuterol 1 0 
Benadryl 1 0 
Cimetidine 1 0 
Lisinopril 0 1 
Aspirin 0 1 
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Data 
  
Table 8. Nerve Growth Factor Measurement. 
 Asthmatic 
Sputum (pg/ml) 
Non-asthmatic 
Sputum (pg/ml) 
Asthmatic EBC 
(pg/ml) 
Non-asthmatic 
EBC (pg/ml) 
1 210 7 0 0 
2  171  0 
3  280  0 
4  198  5 
Figure 1: Mean sputum NGF levels in asthmatics and non-asthmatics 
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Table 9. Statistical Analysis of Sputum Nerve Growth Factor levels for all subjects 
  
 Asthmatic Non-asthmatic 
N 1 4 
Mean 210 164 
Median 210 184.5 
Standard Deviation  114.5 
Variance  13103.3 
Standard Error of the Mean  57.2 
Skewness  -1.008 
Kurtosis  1.837 
Range 0 273 
Minimum 210 7 
Maximum 210 280 
   
   
 
t-value 2.87 
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                                                       DISCUSSION 
Findings 
This study was aimed at determining if NGF is measurable in induced sputum and 
exhaled breath condensate and if so how do levels differ between asthmatics and non-
asthmatics? Demographic data revealed that 5 subjects age 19 – 39 years old participated 
in the study. Medical information review revealed a history of GERD and Grave’s 
disease in the asthmatic while the non-asthmatics reported hypertension and deep venous 
thrombosis. 
The results revealed that NGF was measurable only in sputum. The mean value in 
asthmatics was 210 pg/ml while non-asthmatics had a mean value of 164 pg/ml. The 
independent t-test was used to analyze the data, and a t-value of 2.870 was obtained while 
the critical value was 2.353 given alpha of 0.05. Though a mean difference of 46 was 
found between asthmatic and non-asthmatic subjects, this is not statistically significant 
and we fail to reject the null hypothesis. The power obtained was 0.1135 (11%), however 
in view of the small sample size used   (1 asthmatic and 4 non-asthmatics), the study 
lacked adequate power. If a sample size of 20 was used as planned initially, the power 
will only be raised to 23% (0.2288). The prestudy analysis estimated that a sample size of 
64 is needed to obtain a power of 80% (0.80) for a mean difference of 0.5, given a 
standard deviation of 1 and alpha set at 0.05. The type II error, beta (1-power) was 89% 
(0.8865) but will be reduced to 77% with a sample size of 20.     
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 Implications 
  
 The implication gleaned from this study is that there is no significant difference in 
the sputum NGF levels in asthmatics compared to non-asthmatics and we failed to reject 
the null hypothesis. However, the study does not have adequate power due to the small 
sample size. Though a previous study showed no significant difference in sputum NGF 
levels (pg/ml) in persons with chronic cough including asthma (median 580; inter-
quartile range 312 – 880) compared to healthy controls (median 516; inter-quartile range 
296-772), some other studies suggest that higher levels of NGF are obtained in asthmatics 
[19].    
 Twenty (20) sets of samples were collected and analyzed in 2 batches for this 
study (Batch A: 5; Batch B: 15). The first batch was analyzed successfully; however the 
second batch was inadvertently ruined at analysis by a bad NGF kit which was defective 
from the manufacturer. Unfortunately, a new replacement kit was not immediately 
available and in view of time constraint under the circumstance, the study had to be 
reported with the limited data available.  This incomplete study lacks internal validity. 
 
Future Directions 
In the future, improved micro-concentration collection techniques (lipholization) 
and analytic chemistry methods could increase the likelihood of detecting NGF in EBC, 
however  NGF may be absent in EBC. Further research in this direction is needed.  
Values obtained for NGF in sputum may have been similar to non-asthmatics           
because only persons with stable mild asthma and normal spirometry were included in        
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the study except for one subject. In future studies, asthmatic subject selection should be 
based strictly on spirometric parameters and not just a self reported history.   
 Finally, future studies should be well designed with emphasis on random selection 
of subjects, large sample size and objective criteria for defining asthmatic subjects. 
 
Study Limitations 
Limitations can have a negative effect on the validity of the study. This 
incomplete study is limited by it’s small sample size and thus lacks internal validity. The 
stronger the association is in nature, the easier it is to find with a small sample size.  The 
closer the true association is to the null value, the larger sample size you need to find it to 
be statistically significant [17]. When the sample is too small, a study is more likely to 
miss an association, increasing the likelihood of a Type II error [17]. A Type II error may 
have been committed in this study where a weaker association could still be present and 
would not be detected by this study.   
Study biases may limit the value of a study. This study may have been limited by 
selection bias. Though males and females from various racial backgrounds (Caucasian,   
Blacks, Asians and Hispanics) were used in this study, all subjects were recruited from 
within the University campus and were current or past undergraduate and graduate 
students. Observer bias was also present as this was not a blind study. All of these can 
limit the generalizability of the study [17. 
 Confounders can also affect a study. Several methods may be used to control for    
confounders including restriction, randomization, and matching[17]. Multiple restrictions                                                         
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were used in the study design to attempt to control for confounder but randomization was 
not done because two distinct groups (asthmatics and non-asthmatics) were being 
compared.  Matching, though beneficial was not used either.  
In performing statistical analyses where two distinct groups were compared, three 
underlying assumptions were made:  (1)Assumption of Normality, (2)Assumption of 
Homogeneity of Variance, and (3)Assumption of Independence [18]. Statistical analyses 
are most robust to violations of the Normality Assumption.  Statistical analyses are 
moderately robust to the Homogeneity of Variance Assumption.  Statistical analyses are 
the least robust to the Assumption of Independence, the most serious of the violations.  In 
this study, care was taken not to allow people who were genetically related to each other 
participate in the study.   
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                                                         CONCLUSION 
Given the small sample size and the other limitations listed above, this pilot study 
is limited in its value.  NGF was not detected in EBC. Though a higher mean NGF was 
observed in the sputum of asthmatics, we failed to reject the null hypothesis. NGF may 
be truly absent in EBC otherwise improved analytic chemistry methods may enhance 
detection of NGF in the future. Further studies are needed before NGF measurements in 
sputum can be used routinely in clinical practice. A follow up study using a larger sample 
size will increase the power and ensure internal validity and generalizability of the results 
obtained.  
Measurement of NGF in sputum may be useful in surveillance programs of 
ccupational asthma and the estimation of dose from exposure with Reactive Airways 
Dysfunction Syndrome (RADS). Study results observed in sputum may be used in 
combination with other tools for the diagnosis of occupational asthma. 
If elevated levels of NGF is detected in asthmatics, this will conform with other 
studies done with BAL, nasal lavage and blood. I would expect allergic asthma to be 
associated with higher levels of NGF compared to irritant induced asthma because it 
involves sensitization and a latent period. Mild disease may not result in any significant 
difference in NGF levels compared to non-asthmatics.  Furthermore, coticosteroids 
suppress NGF level elevation / response if given prior to exposure. 
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Appendix A: Pre-study questionnaire 
Subject number:_______ 
PRESTUDY QUESTIONNAIRE 
 
      Date _______________________________________ 
 
 
1) Gender:                Male           Female        (circle one) 
 
2) What is your date of birth? ______________________ 
 
3) How old are you? _____________________________ years old. 
 
4) Do you currently have, or have you ever had any of the following conditions 
listed below?  (Please circle YES or NO) 
 
YES NO CHEST PAIN, PALPITATIONS, IRREGULAR HEART    
BEAT, OR HEART DISEASE? 
 
YES NO HIGH BLOOD PRESSURE? 
 
YES NO ASTHMA 
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YES           NO     BRONCHITIS, EMPHYSEMA, OR OTHER   
LUNG OR BREATHING DISORDERS? 
 
YES  NO DIFFICULT OR HEAVY BREATHING? 
 
YES NO  A LARGE AMOUNT OF PHLEGM PRODUCTION 
 
YES           NO      ANY ALLERGIES? 
 
YES NO ARE YOU PREGNANT? 
 
YES           NO      HISTORY OF HERNIA? 
 
IF YOU HAVE CIRCLED YES TO ANY OF THE ABOVE QUESTIONS, PLEASE 
EXPLAIN: ___________________________________________________________ 
 
___________________________________________________________ 
 
5) Do you have any health problems or past medical history of health problems that 
you have seen a physician for? Please list them below. 
                     1._________________________________________________________ 
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                     2. ________________________________________________________ 
                         
                     3. ________________________________________________________ 
 
                     4. ________________________________________________________ 
 
                      5.________________________________________________________ 
 
6) Are you taking any medications?  If so please list them below. (Including over the 
counter medications) 
 
                     1. ________________________________________________________ 
                      
                     2. ________________________________________________________ 
                        
                     3. ________________________________________________________ 
 
                          4. ________________________________________________________ 
 
                     5. ________________________________________________________ 
                     
   6. ________________________________________________________      
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   7. ________________________________________________________ 
 
7) At this point in time, to what degree do you note the following symptoms?  
 
(a) Phlegm production: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT     ___VERY MUCH 
(b) Runny or irritated nose or nasal passages: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
(c) Throat irritation or burning sensation: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
(d) Sensation of a “weight” or tightness of the chest:  
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
(e) Feeling of chest pain, burning, or tightness: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
 
8) If you have ever smoked, please answer the following: 
 
      How many packs per day did you smoke? ________________________ 
 
      For how many years did you smoke? ____________________________ 
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     When did you stop smoking? __________________________________ 
 
9) On what date were you last ill? _____________________________________ 
 
10)  What illness did you have? ________________________________________ 
 
   Please circle YES or NO to the following questions: 
 
a) Are you exposed to second hand smoke at home or at work?  
   
                  YES      or      NO         
 
b) Were you or are you exposed to any gases, dusts, or fumes at your job? 
                        YES      or       NO 
 
           If so, please explain:   ____________________________________________ 
 
_____________________________________________________________________ 
 
c) Do you ever wheeze or become short of breath?     
         YES      or      NO         
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 This is the end of this questionnaire.  Thank you for taking the time to fill it 
out.  
 Special thanks to Dr. Gwyn Crump for allowing the use of his questionnaire in 
this study.  
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Appendix B: Post-study questionnaire 
 
Post-Study Questionaire  
 
SUBJECT NUMBER:  ________________________________________  
 
Are you currently experiencing any of the following symptoms?  
(Please Circle YES or NO) 
 
(1) Difficult or heavy breathing?  YES    NO 
 
(2) Feeling of chest pain, tightness, pressure, or burning?   
YES      NO  
(3) Wheezing or increased cough? YES    NO 
 
(4) Any new symptoms that were not present when you arrived    
       here today?     YES   NO 
 
(5) Any other unusual symptoms?     YES   NO 
Special Thanks To Dr. Gwyn Crump for developing the majority of this questionnaire! 
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Appendix C: Flyer 
You’re Are Invited To Participate. 
What?  
A $20.00 token will be given to each volunteer who completes the study for valuable time 
spent participating.  
This study makes measurements of the air breathed out by subjects. The tests will measure 
lung function & a constituent of exhaled air and sputum called Nerve Growth Factor (NGF). 
This research study involves getting a breathing treatment but is painless and non-invasive. 
Who? 
Healthy men and women with or without a history of asthma. 
Candidates must be 18-50 yrs old and of any race. 
Why? 
The study is designed to examine whether a certain marker (NGF) found in the air we 
normally breathe out is different in healthy asthmatics compared to non-asthmatics.  Your 
participation in this study may help develop a less invasive test for routine assessment of 
allergic airway disorders such as asthma, which may enable healthcare providers to better 
monitor worsening of disease or exacerbations.  Hopefully, the results will benefit 
science. 
When? 
The study requires only one visit and will last approximately ninety minutes.  
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Where? 
USF College of Public Health  
If you may be interested or have any questions, please contact me (DR. VICTOR 
NWILOH) at: 
pager number: (813) 332-6925  
cell phone number: (678) 472-2387 
 e-mail: vnwiloh@hsc.usf.edu  
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Appendix D: Informed consent form 
 
Informed Consent for an Adult 
University of South Florida 
Information for People Being Asked to Take Part in Research Studies 
IRB Study # 103749 
 
Doctors and researchers at University of South Florida (USF) study diseases and other 
health problems people have.  We try to find better ways to help treat these health 
problems. To do this, we need the help of people who agree to take part in a research 
study.  
Title of Research Study:  Measurement of Nerve Growth Factor in induced sputum and 
exhaled brath condensate. 
Persons in Charge of Study: Victor M. Nwiloh, MD; Stuart M. Brooks, MD and Thomas 
Truncale, D.O. 
Where the study will be done:  University of South Florida, College of Public Health, 
MHH Room 323 
Who is paying for the study:  Sunshine Education Research Center 
Should you take part in this study? 
This form tells you about this research study.  You can decide if you want to take part in 
it.   You do not have to take part.  Reading this form should help you decide if you want  
      45 
  
to take part in the study.  If, at any time, you have any questions feel free to ask the 
person explaining this study to you.  
Before you decide: 
• Read this form. 
• Talk about this study with the study doctor or the person explaining the study.  You 
can have someone with you when you talk about the study. 
• Find out what the study is about. 
This form explains: 
• The purpose of this research study. 
• What will happen during this study and what you will need to do. 
• The potential benefits of being in this study, if any. 
• The risks of having problems because you are in this study. 
• The answers to any questions you might have. 
You can ask questions: 
• You may have questions this form does not answer.  If you do, ask the study doctor as 
you go along. 
• You don’t have to guess at things you don’t understand. Ask the people doing the 
study to explain things in a way you can understand. 
After you read this form, you can:  
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• Take your time to think about the information that has been provided to you.  
• Have a friend or family member read the form. 
   
Talk it over with your regular doctor. 
 
It’s up to you: 
• If you choose to be in the study, then you can sign the form.   
• If you do not want to take part in this study, do not sign the form.   
Why is this research being done? 
The purpose of this study is to find out if there is a difference between asthmatic and non-
asthmatic subjects in relation to a certain substance in the air we breathe out called nerve 
growth factor which is also found in induced sputum. This research could eventually lead 
to the development of a non-invasive method for routine assessment of allergic airways 
diseases such as asthma.  
The air we breathe out is currently the subject of intense research.  There are certain 
substances in this air whose levels are affected by specific diseases associated with the 
lungs.  In this study, one of these substances in exhaled breath is called nerve growth 
factor.  Your exhaled breath will be collected into a single-use, clean, disposable tube that 
has never been used before.  Each tube is discarded after you have used it. Sputum is also 
induced with a nebulizer and collected in a specimen bottle for measurement of nerve  
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growth factor. Two groups of subjects will be  examined in this study because persons 
with allergic diseases such as asthma have been found to have significantly higher levels 
of NGF in other tests.   
Why are you being asked to take part? 
You must be a healthy person within a certain age group to be eligible for the study.  You 
will not be eligible if you have had an acute exacerbation of asthma or febrile illness at 
the time of evaluation or within the preceding 96 hours or if you are pregnant.  You may 
have had a recent respiratory tract disease if you have had any recent fever, chills, 
coughing, shortness of breath or difficulty breathing, nasal congestion, runny nose, sinus 
congestion or headache, colored phlegm or (green, yellow, brown, black, or red), 
crackling or whistling sounds heard when you breathe, diagnosis by a doctor of 
nose/sinus/lung infections, or recent treatment with antibiotics for any of these 
symptoms.  You may not be eligible if you have poorly controlled asthma or any other 
diseases or health problems.  We are asking you to take part in this study because you are 
a healthy young person aged between 18-50 years.  We want to find out if there is a 
difference in the exhaled breath and induced sputum content of NGF between healthy 
asthmatics and non-asthmatic subjects.   
Your regular medical treatment will not actually be part of the research study. In fact 
you will not be eligible for the study if you suffer from any significant heart or lung 
disease or other significant medical problems.  How long will you be asked to stay in 
the study?  You will be asked to spend no longer than 90 minutes in this study.   
During this time you will be required to complete the screening questionnaires, perform a 
      48 
  
limited non-invasive physical examination, a breathing test and the study proper.   
How often will you need to come for study visits? 
A study visit is one you have with the study doctor.  This visit is different than the visits 
you make with your regular doctor.  You will need to come for only one visit.   
At this study visit, the doctor will obtain a questionnaire both before and after testing, 
perform a brief physical exam consisting primarily of listening to your heart and lungs 
using a stethoscope, and perform the breathing tests.   
How many other people will take part? 
About 30 people will take part in this study at USF.    
Will the medical treatment you get from your regular doctor change if you take part in 
this study? 
The kind of treatment you now get from your regular doctor will not change because you 
take part in this study.  You will keep seeing your regular doctor.  Your regular doctor 
will give you the same kind of treatment you would get anyway, whether you take part in 
the study or not. 
If you need it, you can  
• Use other medicines prescribed that will help your disease.   
• Get any surgery you need. 
• You will need to talk to the study doctor about any surgery you have planned. 
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Talk to your regular doctor about the treatments you may need. 
 If you have an emergency, you can get emergency care. 
Other procedures can be used for measuring airway disease.  These include bronchoscopy 
with bronchoalveolar lavage/ bronchial biopsy (which are invasive), or sputum induction 
(which can be less comfortable).  These procedures, which can be ordered by your 
regular doctor if needed clinically, will not be performed here.   
What other choices do you have if you decide not to take part in this study? 
The alternative to being part of this research study is not to participate in this study. 
There will be no changes in your life. You will continue with your regular life style 
and are instructed to visit your personal physician for any respiratory or non-
respiratory problem you were being followed for before the study. The same is true if 
you decide to participate in the study. 
If you decide you do not want to take part in this study that is okay.  There are other 
choices such as chest X-ray, chest CT, bronchoalveolar lavage, biopsy, or sputum 
induction that are considered to be the current standard practices for diagnosing 
airway disease. 
How do you get started? 
You must be within a certain age group to be eligible for the study. You must also be 
healthy to participate in this study.  Volunteers must be between ages 18 and 50. If you 
decide to participate in this study, you will be required to review this informed consent, 
discuss the study and your possible participation with the study doctor and decide  
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whether you are interested in participating.  If you decide to take part in this study, you 
will need to sign this consent form.  This informed consent must be signed before any 
study-related test or procedure can be done. After signing this informed consent, 
screening tests will be completed to help determine if you meet the requirements to be in 
the study. You will be asked to fill out questionnaires, undergo a limited physical 
examination and perform a limited breathing test called spirometry.  Screening tests are 
tests done to see if you are able to be in the study.  In order to qualify, you must record a 
history of good health.  You must record a negative questionnaire response for active 
respiratory diseases. You must not be suffering from any heart condition. 
There are different tests performed. These tests are considered non-invasive and do 
not involve drawing blood or inserting tubes into your throat or nose.  
We will do these screening tests: 
1.   Questionnaires: You will be asked to fill out questionnaires about your health,  
ethnicity, and socioeconomic status.  They will include medical questionnaires.  A 
post-study symptom questionnaire will also be given at the end of each visit. 
2.     Physical Examination: Listening with a stethoscope to your chest and abdomen. 
3. Spirometry: This is a common, frequently used and accepted medical test for 
evaluating how your lungs are working.  Abnormal spirometry may indicate that 
you have a lung disease such as asthma, emphysema, chronic bronchitis, and 
other diseases. The test involves taking in a deep breath and then blowing out 
into a tube as hard and as fast as you can. The spirometer measures the amount 
and speed with which you forcibly exhale your deep breath.   
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You will be notified if your spirometry test results are abnormal and advised to see your 
personal physician.  
The test results will come back right away.  At the end of each of these screening tests, 
you and the research team will decide whether or not you should be in the study.  
What will you need to do to get ready for this study? 
You will need to refrain from strenuous physical exercise (such as running, jogging, 
working out with exercise equipment, participating in sports, or doing any heavy physical 
labor), eating, or drinking for a minimum of one hour prior to the visit. 
You must be within a certain age group to be eligible for the study. You must also be 
healthy to participate in this study.  Volunteers must be between ages 18 and 50. If you 
decide to participate in this study, you will be required to review this informed consent, 
discuss the study and your possible participation with the study doctor and decide 
whether you are interested in participating.  This informed consent must be signed before 
any study-related test or procedure can be done. After signing this informed consent, 
medical tests will be completed to help determine if you meet the requirements to be in 
the study. You will be asked to fill out a questionnaire, undergo a physical examination 
and perform a breathing test.  In order to qualify, you must record a negative respiratory 
questionnaire response to treatment for active respiratory diseases. You must not be 
suffering from any major cardiovascular condition. 
There are different tests performed. These tests are considered non-invasive and do 
not involve drawing blood or inserting tubes into your throat or nose.  
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What will happen during this study?  
Only healthy, non-pregnant subjects without a history of heart or other diseases ages 18-
50 years old will be invited to participate.  You will be asked to verify that they have not 
had any signs of recent asthma exacerbation or febrile illness including upper or lower 
respiratory tract infections.  This would include any recent  fever, chills, coughing, 
shortness of breath or difficulty breathing, nasal congestion, runny nose, sinus congestion 
or headache, colored phlegm or (green, yellow, brown, black, or red), crackling or 
whistling sounds heard when you breathe, diagnosis by a doctor of nose/sinus/lung 
infections, or recent treatment with antibiotics for any of these symptoms.  At a minimum 
of 1 hour prior to visit, subjects will be instructed not to eat or drink or participate in 
strenuous exercise. 
If you decide to participate :  
During the visit, you will be asked to volunteer for the study.   If you volunteer, you will 
be given information about the study procedure, the risks, the benefits, and the 
alternatives to the procedure.  Then you will be asked if you have any questions and 
demonstrate an understanding of everything discussed.  If you still agree to proceed, you 
will be asked to sign an informed consent.   You will be taken to the Breath Laboratory at 
the College of Public Health (MHH Room 323) and seated comfortably in an air-
conditioned room.   
You will be asked to complete a questionnaire including symptoms, medical history to 
determine “health” and age.  Those who fulfill the criteria of age and being “healthy” will 
be asked to participate in the study.  You will then undergo brief physical examination     
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including auscultation.  You will be directly watched by a physician throughout the 
remainder of the study via direct observation.   
Limited spirometry (including FEV1, FVC, and FEV1/FVC ratio), which is part of a 
common method done in hospitals and clinics to check lung function, will be done to help 
verify that your breathing is normal.  A loose-fitting device resembling a clothespin will 
be placed on the nose during the study to obtain better spirometry results.  You will be 
asked to forcibly exhale into a disposable single-use tube using maximum effort after 
maximal inhalation.  Anyone who has abnormal spirometry measurements will be 
notified of this information and advised to consult a healthcare provider and disqualified 
for the remainder of the study.   
Adverse effects are extremely uncommon during this phase of the study because subjects 
are young/ healthy individuals and the room is temperature controlled. You will be seated 
during the spirometry, and this phase of the study is brief in duration, nonetheless, there 
is the remote possibility of unusual symptoms such as lightheadedness, dizziness, chest 
pains, palpitations, or shortness of breath during the spirometry from overexertion in  
 breathing.  As a precaution, you will be instructed to notify the physician examiner 
immediately if you experience any symptoms at any time.  Following this, auscultation 
will be performed again and you will be given another brief symptom questionnaire to 
make sure you have no adverse effects from spirometry. 
Next, the actual study exhaled breath testing, which is strictly part of the research, will be 
performed to measure the amount of nerve growth factor in the breath.  You will be asked 
to breathe out through a disposable plastic mouthpiece connected to a filter at a constant     
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 rate of flow after a maximal inspiration (which is where you take as deep a breath in as 
you can to fill your lungs with as much air as possible).  Afterwards, sputum induction 
will be initiated using a nebulizer and samples will be collected in a specimen bottle. 
Following this, the investigator will again perform a brief physical examination using a 
stethoscope to listen to your heart and lungs and you will be given another brief symptom 
questionnaire to make sure you have no adverse effects after the study.  
Some study visits may be longer or shorter than ninety minutes depending primarily on 
both the equipment and subject variability in breathing.  
You will be asked to verify the absence of symptoms prior to leaving. 
We will study two groups of people: 
People in one group will be asthmatics.  People in the other group will be of non-
asthmatics. 
Usually subjects may exhale different levels of markers that we can measure in the 
breath.   
We want to examine whether levels of the marker nerve growth factor in exhaled breath 
condensate and induced sputum is different between asthmatics and non-asthmatics. 
Right now, we do not know for sure if the measurement of nerve growth factor in exhaled 
breath condensate and induced sputum will accurately measure allergic lung disease.  We 
are doing this study to find out if the measurement of nerve growth factor in your breath 
is differs amongst asthmatics and non-asthmatics.   
If the measurement is not accurate, you may still have airway or lung disease that is  
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undetected by the study.  You should consult your own physician regardless of the study 
results if you have any concerns or experience any symptoms at any time. 
During this study, here is what you will need to do: 
Subjects will be instructed to refrain from eating, drinking, or strenuous exercise for at 
least one hour prior to the visit. 
Will you be paid for taking part in this study? 
We will pay you for the time you volunteer while being in this study.  You will receive a 
total of twenty dollars for completion of the study.   
What will it cost you to take part in this study? 
The study will pay the costs of limited physical exam (primarily auscultation), limited 
spirometry, and the experimental nerve growth factor measurement. 
You will not have to pay the fees for tests in this study that are not a part of regular 
medical care for your disease/condition.   
Those subjects that do not have a parking permit for on-campus parking will have to pay 
for any parking costs incurred as required from the University of South Florida by taking 
part in this study.   
You will have to pay for your regular care or any other costs.  Your insurance plan should 
cover your regular costs.  Your insurance plan will not have to pay for study costs of 
limited physical exam, limited spirometry, or nerve growth factor measurement. 
What are the potential benefits if you take part in this study? 
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We don’t know if you will get any health benefits by taking part in this study.  We do not 
know if nerve growth factor measurement will help in diagnosing airway or lung 
diseases.  That is why we are doing this study.  
This research study should help us learn whether nerve growth factor measurement will 
help in diagnosing allergic airway or lung diseases.   
Since a medical questionnaire, limited physical exam, and limited spirometry will be 
performed, overt abnormalities detected by your examiner will be relayed to you.  You 
will be instructed to consult your regular doctor regarding these findings. 
No matter what, we will learn more about exhaled breath nerve growth factor levels in 
asthmatics and non-asthmatics.  We will learn more about whether differences do or do 
not exist.  What we learn may help others who are actively studying nerve growth factor 
in exhaled breath for potential use in clinical settings. 
What are the risks if you take part in this study? 
The treatment might not help. 
Right now we do not know for sure if the measurements are consistent.  Because of this, 
you will have to consult your regular physician if you are experiencing any shortness of 
breath, other symptoms, or have any concerns about disease status.  If you do, your 
condition/disease may get worse. 
There may be adverse effects. 
You may have problems because of the procedure used in this study.  These problems are 
called adverse effects.  Some adverse effects are just a bother.  Others could harm you.   
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There may be some adverse effects that we don’t know about yet. 
Here are the known adverse effects that could happen with this study: 
This study poses minimal risk to you.  Spirometry is a standard, routine physical test 
commonly performed in hospitals and some clinics.  It is a noninvasive and relatively 
safe procedure and involves the requirement for maximal expiratory effort.  Thus, there is 
a minimal risk that you may breathe too hard during the forced expiratory maneuvers.  
This could result in: [1]“hyperventilation”, where too much carbon dioxide is blown off 
in a short period of time or [2]excessive physical exertion.  Immediate effects you could 
experience from “hyperventilation” or excessive physical exertion may include 
lightheadedness, dizziness, chest pain or pressure, rapid heart beat, or shortness of breath.   
These usually resolve upon discontinuing the procedure.  You are instructed to 
immediately notify the examiner if any symptoms result.  A determination by the 
examiner of whether or not to continue with the study will be made on an individual 
basis. At any time, both you and the examiner have the right to stop the study for any 
reason.  If you were to continue despite these symptoms, loss of consciousness or 
cardiopulmonary arrest could result in rare cases, requiring emergency treatment and/or 
hospitalization.  In such rare cases, permanent effects could result. 
Patients with history of any type of hernia are excluded from the study since they could 
potentially aggravate the hernia using maximal expiratory effort. 
The procedure for collecting exhaled breath nerve growth factor is very similar to the 
procedure for spirometry, except that the subject is asked to breathe out at a slow regular  
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rate instead of the forced maximal exhalation required in spirometry.  Thus, it poses even 
less risk and discomfort to the subject than spirometry. 
Private medical information will be collected during the study to find out your health 
status.  The health information is being collected only as a guide for participation in the 
study.  The questionnaires used in the study must remain confidential.  To maintain your 
confidentiality, the questionnaires and recorded data from the study will be kept in a 
locked file cabinet.  Access to the material will only be made to the investigators of the 
study.  Also, as an additional measure to ensure confidentiality, each person will be given 
a subject number.  This will be the only identifier listed on the questionnaires to link the 
confidential information to the subject.  The master list linking subjects to their subject 
numbers will also be kept in the locked cabinet, but separately.  
During the study, the safety of the normal subjects will be maintained by: [1] the 
presence of a physician at all times of testing; [2] careful direct physician observation and  
monitoring of subjects during testing, and [3] instruction of subjects to immediately 
discontinue the exercise and notify the physician should they experience any shortness of 
breath, chest pain or pressure, dizziness, lightheadedness, or other unusual symptoms.  
Emergency equipment will be present, and a physician will be in attendance for every 
study patient.  
If you have any of these or any other problems, notify your study doctor immediately.  If 
these side effects bother or worry you, or if you have other problems, call your study 
doctor at (813) 974-7545.  If you have an emergency, go to the closest emergency room 
or clinic for treatment. 
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You may also have problems from the medical treatment you would usually get.   
We may need to stop your treatment.  If we find that the breathing tests are causing 
adverse events, we will stop the procedure.  Early stopping criteria include: 
 1. For individual subjects: 
The following criteria will be used to discontinue participation in the 
study: 
[1] You wish to withdraw from the study. 
[2] You do not meet the criteria for inclusion into the study. 
[3] You demonstrate abnormalities on spirometry, physical 
examination, or monitoring through the study. 
[4] You complain of chest pain or pressure, palpitations, or 
tachypnea. 
[5] If you experience other symptoms, they will be assessed by a 
doctor and assisted in any way needed.  A decision will be made 
whether you may continue to participate in the study provided that 
your safety has not been compromised.  In this case, the decision to 
continue would require mutual willingness on your part to continue 
the study. 
 [6] The safety of the researcher is compromised (for example, a 
hostile subject). 
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2. For the study: 
The study will be terminated if the health or safety of the volunteers  
or examiners becomes jeopardized by an unforeseen event. 
Is there any risk to your unborn children if you take part in this study? 
Pregnant women will not be allowed to participate in the study.  There are 
no adverse effects for men with partners of childbearing age. 
If you are a woman 
You are excluded from the study if you are or may be pregnant due to the 
study protocol, since the study results may be affected.  If you are 
pregnant and you inadvertently take part in this study, the risk of adverse 
effects is still minimal, especially if you are in the first trimester of 
pregnancy.  Nonetheless, it could be that your unborn children may have 
problems now or in the future. 
Tell one of the study doctors right away if: 
• You are pregnant 
• You are breastfeeding. 
If you are a woman 
If you take part in this study, you must use a good birth control method, like oral 
contraceptives or condoms. 
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What if you get sick or hurt while you are in the study?  
If you need emergency care:  
• Go to your nearest hospital or emergency room right away.  Call 911 for help.   It is 
important that you tell the doctors at the hospital or emergency room that you are 
participating in a research study.  If possible, take a copy of this consent form with 
you when you go.  You should know that the USF does not provide emergency care.   
• Call the study doctors as soon as you can.  They will need to know that you are hurt 
or ill.  Call Dr. Victor M. Nwiloh, MD or Dr. Stuart Brooks, MD at (813) 974-7545. 
If it is NOT an emergency, and you get hurt or sick while you are taking part in this 
study:  
• Go to your regular doctor.  It is important that you tell your regular doctor that you 
are participating in a research study.  If possible, take a copy of this consent form 
with you when you go.   
• The USF Medical Clinics may not be able to give the kind of help you need. You may 
need to get help somewhere else. 
If you are harmed while taking part in the study: 
The state of Florida enjoys what is called "sovereign immunity."  This means that you 
usually cannot sue the state of Florida.  However, the state has waived sovereign 
immunity (agreed to be sued) in certain situations.  One of those situations is if a state 
employee, such as your study doctor or other USF employee, is negligent in doing his or 
her job in a way that harms you during the study. 
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  The money that you might recover from the state of Florida is limited in amount. 
You can also call the USF Self Insurance Programs (SIP) at 1-813-974-8008 if you think: 
• You were harmed because you took part in this study. 
• Someone from the study did something wrong that caused you harm, or didn’t do 
something they should have done. 
• Ask the SIP to look into what happened.   
What will we do to keep your study records private? 
Federal law says we must keep your study records private.  Private medical information 
will be collected during the study to ascertain the health status of the subjects.  The health 
information is being collected only as a parameter for participation in the study.  It is 
obtained after discussion with the subjects that the study is only open to healthy subjects.  
Thus, the questionnaires in the study must remain confidential.  We will keep the records 
of this study private by keeping them in a locked file cabinet.  Access to the material will 
only be made to the investigators of the study.  Also, as an additional measure to ensure 
confidentiality, each subject will be given a subject number.  This will be the only 
identifier listed on the questionnaires to link the confidential information to the subject.  
The master list linking subjects to their subject numbers will also be kept in the locked 
cabinet, but separately.  
However, certain people may need to see your study records.  By law, anyone who looks 
at your records must keep them completely confidential. 
The only people who will be allowed to see these records are: 
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The medical staff who are taking care of you. 
Certain government and university people who need to know more about the study.  For 
example, individuals who provide oversight on this study may need to look at your 
records.  These include the University of South Florida Institutional Review Board (IRB) 
and the staff that work for the IRB.  Other individuals who work for USF that provide 
other kinds of oversight may also need to look at your records.  Other individuals who 
may look at your records include:  the Florida Department of Health, people from the 
Food and Drug Administration (FDA), the United States Department of Health and 
Human Services, and the United States Department of Labor.  This is done to make sure 
that we are doing the study in the right way.  They also need to make sure that we are 
protecting your rights and your safety.) 
People at the company who paid for this study at the Sunshine Education and Research 
Center (funded by the National Institute of Occupational Safety and Health, a  
governmental department under the United States Department of Labor may look at the 
study records and pertinent portions of your medical records to make sure the study is 
done in the right way.  
We may publish what we find out from this study.  If we do, we will not let anyone know 
your name.  We will not publish anything else that would let people know who you are.   
What happens if you decide not to take part in this study? 
You should only take part in this study if you want to take part.   
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If you decide not to take part: 
• You will not be in trouble or lose any rights you normally have.  
• You will still have the same health care benefits. 
• You can still get your regular treatments from your regular doctor. 
What if you join the study and decide you want to stop later on? 
You can decide after signing this informed consent document that you no longer want to 
take part in this study.  If you decide you want to stop taking part in the study, tell the 
study staff as soon as you can.  If you decide to stop, you can continue getting care from 
your regular doctor. 
Are there reasons we might take you out of the study later on? 
Even if you want to stay in the study, there may be reasons we will need to take you out 
of it.   You may be taken out of this study if: 
• We find out it is not safe for you to stay in the study.  For example, your health may 
worsen.  Or we may find out that the device used to measure spirometry or exhaled  
       breath condensate might harm you.  Then you may be taken out of the study. 
• You are not coming for your study visits when scheduled. 
You can get the answers to your questions. 
If you have any questions about this study, call Dr. Victor Nwiloh at (813) 974-7545. 
If you have questions about your rights as a person who is taking part in a study, call the  
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Division of Research Compliance of the University of South Florida at (813) 974-9343. 
Signatures for Consent to Take Part in this Research Study 
It is up to you to decide whether you want to take part in this study.  If you want to take 
part, please read the statements below and sign the form if the statements are true. 
I freely give my consent to take part in this study.  I understand that this I am agreeing to 
take part in research.  I have received a copy of this consent form to take with me. 
I choose to participate in the study : a single visit which will last approximately ninety 
minutes. 
____________________________________________     ___________ 
Signature of Person Taking Part in Study   Date 
____________________________________________   
Printed Name of Person Taking Part in Study 
________________________________________                   ____________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can 
expect. 
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I hereby certify that when this person signs this form, to the best of my knowledge, he or 
she understands:  
What the study is about. 
What needs to be done. 
What the potential benefits might be.  
What the known risks might be.   
I also certify that he or she does not have any problems that could make it hard to 
understand what it means to take part in this study. This person speaks the language 
that was used to explain this study. 
This person reads well enough to understand this form or, if not, this person is able to 
hear and understand when the form is read to him or her. 
This person does not have a medical problem that makes it hard to understand what is 
being explained and can, therefore, give informed consent.   
This person is not taking drugs that make it hard to understand what is being 
explained and can, therefore, give informed consent.   
____________________________________________     ___________ 
Signature of Person Obtaining Informed Consent  Date 
__________________________________________________ 
Printed Name of Person Obtaining Informed Consent 
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____________________________________________     ___________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness] 
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